 |
AbbVie |
ABBV-154 |
Biodrugs/ Drugs |
Autoimmune & Inflammation |
Polimialgia reumática y Enfermedad de Crohn |
2PhII |
ABBV-154
Therapeutic area:
Autoimmune & Inflammation
|
|
AbbVie |
ABBV-155 |
Biodrugs/ Drugs |
Cancer |
Solid and Hematologic Tumors |
1PhI |
ABBV-155
Therapeutic area:
Cancer
|
|
AbbVie |
ABBV-151 |
Biodrugs/ Drugs |
Cancer |
Solid Tumours |
2PhII |
ABBV-151
Therapeutic area:
Cancer
|
|
AbbVie |
AL002 |
Biodrugs/ Drugs |
Central Nervous System |
Alzheimer's disease |
2PhII |
AL002
Therapeutic area:
Central Nervous System
|
|
AbbVie |
ABBV-400 |
Biodrugs/ Drugs |
Cancer |
Solid Tumours |
1PhI |
ABBV-400
Therapeutic area:
Cancer
|
|
AbbVie |
Telisotuzumab vedotin (ABBV-399) |
Biodrugs/ Drugs |
Cancer |
Non-Small Cell Lung Cancer |
3PhIII |
Telisotuzumab vedotin (ABBV-399)
Therapeutic area:
Cancer
|
|
AbbVie |
ABBV-927 |
Biodrugs/ Drugs |
Cancer |
Solid Tumours |
2PhII |
ABBV-927
Therapeutic area:
Cancer
|
|
AbbVie |
ABBV-181 |
Biodrugs/ Drugs |
Cancer |
Solid Tumours |
1PhI |
ABBV-181
Therapeutic area:
Cancer
|
|
AbbVie |
Epcoritamab |
Biodrugs/ Drugs |
Cancer |
"First-line Large B-cell Lymphoma
US , EU
Relapsed ∕ Refractory Follicular Lymphoma
N ∕ A
B-cell Non-Hodgkin lymphoma
N ∕ A
Relapsed ∕ Refractory Chronic Lymphocytic Leukemia
N ∕ A
Richter's Syndrome" |
3PhIII |
Epcoritamab
Therapeutic area:
Cancer
|
|
AbbVie |
ABBV-916 |
Biodrugs/ Drugs |
Central Nervous System |
Alzheimer's disease |
2PhII |
ABBV-916
Therapeutic area:
Central Nervous System
|
|
AbbVie |
ABBV-368 |
Biodrugs/ Drugs |
Cancer |
Solid Tumours |
1PhI |
ABBV-368
Therapeutic area:
Cancer
|
|
AbbVie |
ABBV-CX-2029 |
Biodrugs/ Drugs |
Cancer |
Solid and Hematologic Tumors |
2PhII |
ABBV-CX-2029
Therapeutic area:
Cancer
|
|
AbbVie |
Elezanumab (ABT-555) |
Biodrugs/ Drugs |
Central Nervous System |
"Spinal Cord Injury
N ∕ A
Acute Ischemic Stroke" |
2PhII |
Elezanumab (ABT-555)
Therapeutic area:
Central Nervous System
|
|
AbbVie |
Lutikizumab |
Biodrugs/ Drugs |
Autoimmune & Inflammation |
Hidradenitis Suppurativa |
2PhII |
Lutikizumab
Therapeutic area:
Autoimmune & Inflammation
|
|
AbbVie |
ABBV-383 |
Biodrugs/ Drugs |
Cancer |
Multiple Myeloma |
1PhI |
ABBV-383
Therapeutic area:
Cancer
|
|
AbbVie |
Eftoza |
Biodrugs/ Drugs |
Cancer |
Solid and Hematologic Tumors |
1PhI |
Eftoza
Therapeutic area:
Cancer
|
|
AbbVie |
ALPN-101 |
Biodrugs/ Drugs |
Autoimmune & Inflammation |
Systemic lupus erythematosus |
2PhII |
ALPN-101
Therapeutic area:
Autoimmune & Inflammation
|
|
AbbVie |
ABBV-647 |
Biodrugs/ Drugs |
Cancer |
Solid Tumours |
1PhI |
ABBV-647
Therapeutic area:
Cancer
|
|
AbbVie |
AGN-151607 |
Biodrugs/ Drugs |
Others |
Post-Operative Atrial Fibrillation |
2PhII |
AGN-151607
Therapeutic area:
Others
|
|
AbbVie |
Skyrizi |
Biodrugs/ Drugs |
Autoimmune & Inflammation |
Ulcerative colitis |
3PhIII |
Skyrizi
Therapeutic area:
Autoimmune & Inflammation
|
|
AbbVie |
ABBV-637 |
Biodrugs/ Drugs |
Cancer |
Solid Tumours |
1PhI |
ABBV-637
Therapeutic area:
Cancer
|
 |
Amgen |
erenumab |
Biodrugs/ Drugs |
Analgesia & Pain
Central Nervous System |
Episodic migraine (high frequency) |
4Reg. |
erenumab
Therapeutic area:
Analgesia & Pain / Central Nervous System
|
|
Amgen |
Evenity |
Biodrugs/ Drugs |
Genetic Diseases and Dysmorphic syndromes |
A Randomized, Double blind, Placebo controlled, Ascending Multiple dose Study to Evaluate Safety, Pharmacokinetics, and Pharmacodynamics of Romosozumab in Children and Adolescents with Osteogenesis Imperfecta |
1PhI |
Evenity
Therapeutic area:
Genetic Diseases and Dysmorphic syndromes
|
|
Amgen |
bemarituzumab |
Biodrugs/ Drugs |
Cancer
Digestive System |
Advanced and untreated gastric and gastroesophageal junction cancer with overexpression of FGFR2b |
1PhI |
bemarituzumab
Therapeutic area:
Cancer / Digestive System
|
|
Amgen |
carfilzomib |
Biodrugs/ Drugs |
Blood and Lymphatic systems
Cancer |
Recurrent or refractory acute lymphoblastic leukemia |
1PhI |
carfilzomib
Therapeutic area:
Blood and Lymphatic systems / Cancer
|
|
Amgen |
tarlatamab |
Biodrugs/ Drugs |
Cancer |
Neuroendocrine Prostate Cancer (PNES) |
1PhI |
tarlatamab
Therapeutic area:
Cancer
|
|
Amgen |
bemarituzumab |
Biodrugs/ Drugs |
Cancer
Digestive System |
Previously untreated advanced gastric or gastroesophageal junction cancer with overexpression of FGFR2b |
3PhIII |
bemarituzumab
Therapeutic area:
Cancer / Digestive System
|
|
Amgen |
apremilast |
Biodrugs/ Drugs |
Autoimmune & Inflammation
Musculoskeletal Disorders |
" EB:inflamación en los vasos sanguineos, se manifiestan ulceras bucales/genitales y lesiones en los ojos/piel
AIJ:inflamación de las articulaciones con desorden psoriasico que afecta a pts pediatricos " |
3PhIII |
apremilast
Therapeutic area:
Autoimmune & Inflammation / Musculoskeletal Disorders
|
|
Amgen |
tarlatamab |
Biodrugs/ Drugs |
Cancer
Respiratory and Pulmonary system |
Small cell lung cancer |
1PhI |
tarlatamab
Therapeutic area:
Cancer / Respiratory and Pulmonary system
|
|
Amgen |
bemarituzumab |
Biodrugs/ Drugs |
Cancer |
Squamous non-small cell lung cancer |
1PhI |
bemarituzumab
Therapeutic area:
Cancer
|
|
Amgen |
apremilast |
Biodrugs/ Drugs |
Autoimmune & Inflammation |
Subjects with active Behçet's disease |
3PhIII |
apremilast
Therapeutic area:
Autoimmune & Inflammation
|
|
Amgen |
tarlatamab |
Biodrugs/ Drugs |
Cancer
Respiratory and Pulmonary system |
Relapsed/refractory small cell lung cancer |
3PhIII |
tarlatamab
Therapeutic area:
Cancer / Respiratory and Pulmonary system
|
|
Amgen |
apremilast |
Biodrugs/ Drugs |
Autoimmune & Inflammation |
Juvenile psoriatic arthritis |
3PhIII |
apremilast
Therapeutic area:
Autoimmune & Inflammation
|
|
Amgen |
acapatamab |
Biodrugs/ Drugs |
Cancer |
Metastatic castration-resistant prostate cancer (mCRPC) |
2PhII |
acapatamab
Therapeutic area:
Cancer
|
|
Amgen |
talimogén laherparepvec |
Biodrugs/ Drugs |
Cancer
Dermatology |
Melanoma stage IIIB to IVM1d unresectable/metastatic |
2PhII |
talimogén laherparepvec
Therapeutic area:
Cancer / Dermatology
|
|
Amgen |
AMG 305 |
Biodrugs/ Drugs |
Cancer |
Phase 1 First-In-Human Study to Explore the Safety, Tolerability, and Pharmacokinetics of AMG 305 in Subjects With Advanced Solid Tumors |
1PhI |
AMG 305
Therapeutic area:
Cancer
|
|
Amgen |
AMG 133 |
Biodrugs/ Drugs |
Metabolic / Endocrinology |
Obesity |
2PhII |
AMG 133
Therapeutic area:
Metabolic / Endocrinology
|
|
Amgen |
talimogene laherparepec |
Biodrugs/ Drugs |
Cancer
Digestive System |
Hepatocellular carcinoma (HCC) and metastatic liver tumors (non-HCC) |
1PhI |
talimogene laherparepec
Therapeutic area:
Cancer / Digestive System
|
|
Amgen |
efavaleucina alfa |
Biodrugs/ Drugs |
Autoimmune & Inflammation
Digestive System |
Ulcerative colitis |
2PhII |
efavaleucina alfa
Therapeutic area:
Autoimmune & Inflammation / Digestive System
|
|
Amgen |
Xaluritamig |
Biodrugs/ Drugs |
Cancer |
A Phase 1 Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 509 in Subjects With Metastatic Castration-Resistant Prostate Cancer |
1PhI |
Xaluritamig
Therapeutic area:
Cancer
|
|
Amgen |
tarlatamab |
Biodrugs/ Drugs |
Cancer
Respiratory and Pulmonary system |
Small cell lung cancer |
1PhI |
tarlatamab
Therapeutic area:
Cancer / Respiratory and Pulmonary system
|
|
Amgen |
AMG 256 |
Biodrugs/ Drugs |
Cancer |
Advanced solid tumors |
1PhI |
AMG 256
Therapeutic area:
Cancer
|
|
Amgen |
sotorasib |
Biodrugs/ Drugs |
Cancer
Respiratory and Pulmonary system |
Previously treated, locally advanced and unresectable or metastatic non-small cell lung cancer (NSCLC) with the p.G12C mutation in KRAS |
3PhIII |
sotorasib
Therapeutic area:
Cancer / Respiratory and Pulmonary system
|
|
Amgen |
carfilzomib |
Biodrugs/ Drugs |
Blood and Lymphatic systems
Cancer |
Multiple myeloma in relapse |
2PhII |
carfilzomib
Therapeutic area:
Blood and Lymphatic systems / Cancer
|
|
Amgen |
sotorasib |
Biodrugs/ Drugs |
Cancer
Digestive System |
Subjects with previously treated metastatic colorectal cancer with KRAS G12C mutation |
3PhIII |
sotorasib
Therapeutic area:
Cancer / Digestive System
|
|
Amgen |
sotorasib |
Biodrugs/ Drugs |
Cancer
Digestive System
Respiratory and Pulmonary system |
Non-small cell lung cancer, colorectal cancer, and other solid tumors |
1PhI |
sotorasib
Therapeutic area:
Cancer / Digestive System / Respiratory and Pulmonary system
|
|
Amgen |
AMG 404 |
Biodrugs/ Drugs |
Cancer |
Advanced solid tumors |
1PhI |
AMG 404
Therapeutic area:
Cancer
|
|
Amgen |
carfilzomib |
Biodrugs/ Drugs |
Blood and Lymphatic systems
Cancer |
Relapsed or refractory multiple myeloma |
3PhIII |
carfilzomib
Therapeutic area:
Blood and Lymphatic systems / Cancer
|
|
Amgen |
sotorasib |
Biodrugs/ Drugs |
Cancer
Respiratory and Pulmonary system |
Advanced solid tumors with the KRAS G12C mutation |
1PhI |
sotorasib
Therapeutic area:
Cancer / Respiratory and Pulmonary system
|
|
Amgen |
sotorasib |
Biodrugs/ Drugs |
Cancer
Respiratory and Pulmonary system |
Untreated stage IV non-small cell lung cancer (NSCLC) with p.G12C mutation in KRAS |
2PhII |
sotorasib
Therapeutic area:
Cancer / Respiratory and Pulmonary system
|
|
Amgen |
Rocatinlimab |
Biodrugs/ Drugs |
Dermatology |
Atopic Dermatitis |
3PhIII |
Rocatinlimab
Therapeutic area:
Dermatology
|
|
Amgen |
blinatumomab |
Biodrugs/ Drugs |
Blood and Lymphatic systems |
Newly diagnosed Philadelphia Chromosome (Ph) Negative B-Precursor Acute Lymphoblastic Leukemia (ALL) |
3PhIII |
blinatumomab
Therapeutic area:
Blood and Lymphatic systems
|
|
Amgen |
sotorasib |
Biodrugs/ Drugs |
Cancer
Respiratory and Pulmonary system |
Previously treated locally advanced unresectable or metastatic non-small cell lung cancer with the KRAS p.G12C mutation |
3PhIII |
sotorasib
Therapeutic area:
Cancer / Respiratory and Pulmonary system
|
|
Amgen |
romiplostim |
Biodrugs/ Drugs |
Blood and Lymphatic systems |
Chemotherapy-induced thrombocytopenia (CIT) |
3PhIII |
romiplostim
Therapeutic area:
Blood and Lymphatic systems
|
|
Amgen |
Olpasiran |
Biodrugs/ Drugs |
Cardiovascular and circulatory systems |
Cardiovascular disease (atherosclerotic cardiovascular disease (ASCVD) and elevated lipoprotein |
3PhIII |
Olpasiran
Therapeutic area:
Cardiovascular and circulatory systems
|
|
Amgen |
blinatumomab |
Biodrugs/ Drugs |
Blood and Lymphatic systems
Cancer |
Refractory/Relapsed Precursor B-Acute Lymphoblastic Leukemia (B-ALL R/R) |
1PhI |
blinatumomab
Therapeutic area:
Blood and Lymphatic systems / Cancer
|
|
Amgen |
bemarituzumab |
Biodrugs/ Drugs |
Cancer
Digestive System |
overexpression of FGFR2b (FORTITUDE-301) |
1PhI |
bemarituzumab
Therapeutic area:
Cancer / Digestive System
|
|
Amgen |
Repatha |
Biodrugs/ Drugs |
Cardiovascular and circulatory systems |
A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Impact of Evolocumab on Major Cardiovascular Events in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or Stroke |
3PhIII |
Repatha
Therapeutic area:
Cardiovascular and circulatory systems
|
|
Amgen |
etelcalcetida |
Biodrugs/ Drugs |
Blood and Lymphatic systems |
Secondary hyperparathyroidism undergoing hemodialysis |
3PhIII |
etelcalcetida
Therapeutic area:
Blood and Lymphatic systems
|
|
Amgen |
blinatumomab |
Biodrugs/ Drugs |
Blood and Lymphatic systems
Cancer |
Adults with Refractory/Relapsed B-Precursor ALL (B-ALL R/R) |
1PhI |
blinatumomab
Therapeutic area:
Blood and Lymphatic systems / Cancer
|
|
Amgen |
erenumab |
Biodrugs/ Drugs |
Analgesia & Pain
Central Nervous System |
Migraine |
4Reg. |
erenumab
Therapeutic area:
Analgesia & Pain / Central Nervous System
|
|
Amgen |
AMG 199 |
Biodrugs/ Drugs |
Cancer
Digestive System |
Gastric and gastroesophageal junction cancer |
1PhI |
AMG 199
Therapeutic area:
Cancer / Digestive System
|
 |
Celavista Mito-Biogénesis |
Retriacyl |
Biodrugs/ Drugs |
Ophthalmology and optometry |
Retinitis Pigmentosa |
3PhIII |
Retriacyl
Therapeutic area:
Ophthalmology and optometry
|
 |
Gilead Sciences |
Magrolimab + chemotherapy/SG combinations |
Biodrugs/ Drugs |
Cancer |
Metastatic triple-negative breast cancer |
2PhII |
Magrolimab + chemotherapy/SG combinations
Therapeutic area:
Cancer
|
|
Gilead Sciences |
Sacituzumab govitecan-hziy + pembrolizumab |
Biodrugs/ Drugs |
Cancer |
1L metastatic triple-negative breast cancer (PD-L1+) |
3PhIII |
Sacituzumab govitecan-hziy + pembrolizumab
Therapeutic area:
Cancer
|
|
Gilead Sciences |
Magrolimab + chemotherapy |
Biodrugs/ Drugs |
Cancer |
Solid tumors |
2PhII |
Magrolimab + chemotherapy
Therapeutic area:
Cancer
|
|
Gilead Sciences |
Sacituzumab govitecan-hziy |
Biodrugs/ Drugs |
Cancer |
1L metastatic triple-negative breast cancer (PD-L1-) |
3PhIII |
Sacituzumab govitecan-hziy
Therapeutic area:
Cancer
|
|
Gilead Sciences |
Magrolimab + azacitidine |
Biodrugs/ Drugs |
Genetic Diseases and Dysmorphic syndromes |
1L higher risk myelodysplastic syndrome |
3PhIII |
Magrolimab + azacitidine
Therapeutic area:
Genetic Diseases and Dysmorphic syndromes
|
|
Gilead Sciences |
Selgantolimod |
Biodrugs/ Drugs |
Others |
HBV cure |
2PhII |
Selgantolimod
Therapeutic area:
Others
|
|
Gilead Sciences |
Sacituzumab govitecan-hziy |
Biodrugs/ Drugs |
Cancer |
2-3L non-small cell lung cancer |
3PhIII |
Sacituzumab govitecan-hziy
Therapeutic area:
Cancer
|
|
Gilead Sciences |
Magrolimab + azacitidine |
Biodrugs/ Drugs |
Cancer |
1L TP53m acute myeloid leukemia |
3PhIII |
Magrolimab + azacitidine
Therapeutic area:
Cancer
|
|
Gilead Sciences |
Cilofexor / firsocostat / semaglutide combination |
Biodrugs/ Drugs |
Others |
Nonalcoholic steatohepatitis |
2PhII |
Cilofexor / firsocostat / semaglutide combination
Therapeutic area:
Others
|
|
Gilead Sciences |
Domvanalimab + zimberelimab + chemotherapy |
Biodrugs/ Drugs |
Cancer |
1L non-small cell lung cancer |
3PhIII |
Domvanalimab + zimberelimab + chemotherapy
Therapeutic area:
Cancer
|
|
Gilead Sciences |
AB308 + zimberelimab |
Biodrugs/ Drugs |
Cancer |
Advanced cancers |
1PhI |
AB308 + zimberelimab
Therapeutic area:
Cancer
|
|
Gilead Sciences |
Vesatolimod |
Biodrugs/ Drugs |
Autoimmune & Inflammation |
HIV cure |
2PhII |
Vesatolimod
Therapeutic area:
Autoimmune & Inflammation
|
|
Gilead Sciences |
Sacituzumab govitecan-hziy + pembrolizumab |
Biodrugs/ Drugs |
Cancer |
1L non-small cell lung cancer |
2PhII |
Sacituzumab govitecan-hziy + pembrolizumab
Therapeutic area:
Cancer
|
|
Gilead Sciences |
CCR8 (GS-1811) |
Biodrugs/ Drugs |
Cancer |
Advanced Cancers |
1PhI |
CCR8 (GS-1811)
Therapeutic area:
Cancer
|
|
Gilead Sciences |
Lenacapavir |
Biodrugs/ Drugs |
Autoimmune & Inflammation |
Long-acting HIV treatment for virologically suppressed people living with HIV |
2PhII |
Lenacapavir
Therapeutic area:
Autoimmune & Inflammation
|
|
Gilead Sciences |
Magrolimab + chemotherapy/IO combinations |
Biodrugs/ Drugs |
Cancer |
Head and neck squamous cell carcinoma |
2PhII |
Magrolimab + chemotherapy/IO combinations
Therapeutic area:
Cancer
|
|
Gilead Sciences |
MCL1 inhibitor (GS-9716) |
Biodrugs/ Drugs |
Cancer |
Advanced cancers |
1PhI |
MCL1 inhibitor (GS-9716)
Therapeutic area:
Cancer
|
|
Gilead Sciences |
Obeldesivir |
Biodrugs/ Drugs |
Others |
COVID-19 |
3PhIII |
Obeldesivir
Therapeutic area:
Others
|
|
Gilead Sciences |
Trodelvy |
Biodrugs/ Drugs |
Cancer |
2L metastatic urothelial carcinoma |
3PhIII |
Trodelvy
Therapeutic area:
Cancer
|
|
Gilead Sciences |
Axicabtagene ciloleucel |
Biodrugs/ Drugs |
Cancer |
2L+ high-risk follicular lymphoma |
3PhIII |
Axicabtagene ciloleucel
Therapeutic area:
Cancer
|
|
Gilead Sciences |
Lenacapavir / bictegravir |
Biodrugs/ Drugs |
Autoimmune & Inflammation |
HIV treatment for virologically suppressed treatment-experienced people living with HIV |
3PhIII |
Lenacapavir / bictegravir
Therapeutic area:
Autoimmune & Inflammation
|
|
Gilead Sciences |
Sacituzumab govitecan-hziy + combinations |
Biodrugs/ Drugs |
Cancer |
1L metastatic urothelial carcinoma |
2PhII |
Sacituzumab govitecan-hziy + combinations
Therapeutic area:
Cancer
|
|
Gilead Sciences |
Axicabtagene ciloleucel |
Biodrugs/ Drugs |
Cancer |
1L high-risk large B-cell lymphoma |
3PhIII |
Axicabtagene ciloleucel
Therapeutic area:
Cancer
|
|
Gilead Sciences |
Etrumadenant + zimberelimab combinations |
Biodrugs/ Drugs |
Cancer |
Metastatic colorectal cancer |
2PhII |
Etrumadenant + zimberelimab combinations
Therapeutic area:
Cancer
|
|
Gilead Sciences |
Brexucabtagene autoleucel |
Biodrugs/ Drugs |
Cancer |
Pediatric acute lymphocytic leukemia |
2PhII |
Brexucabtagene autoleucel
Therapeutic area:
Cancer
|
|
Gilead Sciences |
Sacituzumab govitecan-hziy |
Biodrugs/ Drugs |
Cancer |
Basket (Solid tumors) |
2PhII |
Sacituzumab govitecan-hziy
Therapeutic area:
Cancer
|
|
Gilead Sciences |
Brexucabtagene autoleucel |
Biodrugs/ Drugs |
Cancer |
Basket (rare B-cell malignancies) |
2PhII |
Brexucabtagene autoleucel
Therapeutic area:
Cancer
|
|
Gilead Sciences |
Sacituzumab govitecan-hziy + pembrolizumab |
Biodrugs/ Drugs |
Cancer |
Adjuvant triple-negative breast cancer |
3PhIII |
Sacituzumab govitecan-hziy + pembrolizumab
Therapeutic area:
Cancer
|
|
Gilead Sciences |
Magrolimab + chemotherapy |
Biodrugs/ Drugs |
Cancer |
Solid tumors |
2PhII |
Magrolimab + chemotherapy
Therapeutic area:
Cancer
|
 |
Incyte Biosciences Iberia |
INCMGA0012 |
Biodrugs/ Drugs |
Cancer |
Anal cancer (In collaboration with MacroGenics) |
2PhII |
INCMGA0012
Therapeutic area:
Cancer
|
|
Incyte Biosciences Iberia |
Itacitinib |
Biodrugs/ Drugs |
Cancer |
Chronic graft-versus-host disease |
3PhIII |
Itacitinib
Therapeutic area:
Cancer
|
|
Incyte Biosciences Iberia |
INCB01158 |
Biodrugs/ Drugs |
Cancer |
Solid tumors (Co-development with Calithera) |
2PhII |
INCB01158
Therapeutic area:
Cancer
|
|
Incyte Biosciences Iberia |
Itacitinib |
Biodrugs/ Drugs |
Cancer |
Non-small cell lung cancer (with osimertinib) (In collaboration with AstraZeneca) |
2PhII |
Itacitinib
Therapeutic area:
Cancer
|
|
Incyte Biosciences Iberia |
INCAGN1876 |
Biodrugs/ Drugs |
Cancer |
Solid tumors (Discovery alliance with Agenus) |
2PhII |
INCAGN1876
Therapeutic area:
Cancer
|
|
Incyte Biosciences Iberia |
Pemigatinib |
Biodrugs/ Drugs |
Cancer |
Bladder cancer |
2PhII |
Pemigatinib
Therapeutic area:
Cancer
|
|
Incyte Biosciences Iberia |
Pemigatinib |
Biodrugs/ Drugs |
Cancer |
Cholangiocarcinoma |
2PhII |
Pemigatinib
Therapeutic area:
Cancer
|
|
Incyte Biosciences Iberia |
Pemigatinib |
Biodrugs/ Drugs |
Cancer |
8p11 MPN |
2PhII |
Pemigatinib
Therapeutic area:
Cancer
|
|
Incyte Biosciences Iberia |
Parsaclisib |
Biodrugs/ Drugs |
Cancer |
Follicular lymphoma |
2PhII |
Parsaclisib
Therapeutic area:
Cancer
|
|
Incyte Biosciences Iberia |
Parsaclisib |
Biodrugs/ Drugs |
Cancer |
Marginal zone lymphoma |
2PhII |
Parsaclisib
Therapeutic area:
Cancer
|
|
Incyte Biosciences Iberia |
Parsaclisib |
Biodrugs/ Drugs |
Cancer |
Mantle cell lymphoma |
2PhII |
Parsaclisib
Therapeutic area:
Cancer
|
|
Incyte Biosciences Iberia |
INCMGA0012 |
Biodrugs/ Drugs |
Cancer |
MSI-H endometrial cancer (In collaboration with MacroGenics) |
1PhI |
INCMGA0012
Therapeutic area:
Cancer
|
|
Incyte Biosciences Iberia |
INCMGA0012 |
Biodrugs/ Drugs |
Cancer |
Merkel cell carcinoma (In collaboration with MacroGenics) |
2PhII |
INCMGA0012
Therapeutic area:
Cancer
|
 |
Merck KGaA |
M1774 (ATR inhibitor) |
Biodrugs/ Drugs |
Cancer |
DDRiver Solid Tumors 320. ATR inhibitor in combination with Dna Damage Response Inhibitors or Immune Checkpoint Inhibitors |
1PhI |
M1774 (ATR inhibitor)
Therapeutic area:
Cancer
|
|
Merck KGaA |
M1774 (ATR inhibitor) |
Biodrugs/ Drugs |
Cancer |
DDRiver Solid Tumors 301. ATR inhibitor monotherapy and in combination with niraparib |
1PhI |
M1774 (ATR inhibitor)
Therapeutic area:
Cancer
|
|
Merck KGaA |
Tepotinib (MET kinase inhibitor) |
Biodrugs/ Drugs |
Cancer |
Non-small cell lung cancer, EGFR mutant, MET amplified |
2PhII |
Tepotinib (MET kinase inhibitor)
Therapeutic area:
Cancer
|
|
Merck KGaA |
M9140 (anti-CEACAM5 Ab drug conjugate) |
Biodrugs/ Drugs |
Cancer |
Solid tumors |
1PhI |
M9140 (anti-CEACAM5 Ab drug conjugate)
Therapeutic area:
Cancer
|
|
Merck KGaA |
Xevinapant (IAP inhibitor) |
Biodrugs/ Drugs |
Cancer |
Resected, cisplatin-ineligible locally advanced SCCHN |
3PhIII |
Xevinapant (IAP inhibitor)
Therapeutic area:
Cancer
|
|
Merck KGaA |
Evobrutinib (BTK inhibitor) |
Biodrugs/ Drugs |
Central Nervous System |
Relapsing multiple sclerosis |
3PhIII |
Evobrutinib (BTK inhibitor)
Therapeutic area:
Central Nervous System
|
|
Merck KGaA |
Avelumab (anti-PD-L1 inhibitor) |
Biodrugs/ Drugs |
Cancer |
Javelin clinical program - avelumab in: solid tumors, renal cell carcinoma, urothelial carcinoma, merkel cell carcinoma, gastric, Head & Neck, lung, ovarian, gastroesophagic junction) |
4Reg. |
Avelumab (anti-PD-L1 inhibitor)
Therapeutic area:
Cancer
|
|
Merck KGaA |
Xevinapant (IAP inhibitor) |
Biodrugs/ Drugs |
Cancer |
Unresected, cisplatin-eligible locally advanced squamous cell carcinoma of the head and neck (SCCHN) |
3PhIII |
Xevinapant (IAP inhibitor)
Therapeutic area:
Cancer
|
|
Merck KGaA |
Enpatoran (TLR7/8 antagonist) |
Biodrugs/ Drugs |
Others |
Systemic lupus erythematosus |
2PhII |
Enpatoran (TLR7/8 antagonist)
Therapeutic area:
Others
|
 |
MSD |
Pembrolizumab/Lenvatinib |
Biodrugs/ Drugs |
Cancer |
Lenvatinib plus Pembrolizumab for first Line Metastatic or Unresectable, Recurrent Head and Neck Squamous Cell Carcinoma |
3PhIII |
Pembrolizumab/Lenvatinib
Therapeutic area:
Cancer
|
|
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
Pembrolizumab in subjects with relapsed or refractory classical Hodgkin Lymphoma |
3PhIII |
Pembrolizumab
Therapeutic area:
Cancer
|
|
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
|
Pemetrexed + Platinum Chemotherapy with or without Pembrolizumab in first line (1L) metastatic non-squamous NSCLC |
3PhIII |
Pembrolizumab
Therapeutic area:
|
|
MSD |
Pembrolizumab/Olaparib |
Biodrugs/ Drugs |
Cancer |
Pembrolizumab/Chemotherapy Followed by Pembrolizumab and Maintenance Olaparib for Squamous Non Small cell Lung cancer |
3PhIII |
Pembrolizumab/Olaparib
Therapeutic area:
Cancer
|
|
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
Subcutaneous Injection Versus Intravenous Infusion in Participants with Advanced Melanoma |
1PhI |
Pembrolizumab
Therapeutic area:
Cancer
|
|
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
Pembro Combination Dose Escalation/MTD (IT)-Solid tumour-Rigontec GmbH-INTRATUMOR |
1PhI |
Pembrolizumab
Therapeutic area:
Cancer
|
|
MSD |
Posaconazole |
Biodrugs/ Drugs |
Infections |
Prophylaxis of invasive fungal infections in immunocompromised pediatric subjects with neutropenia or expected neutropenia |
1PhI |
Posaconazole
Therapeutic area:
Infections
|
|
MSD |
HIF Triplet (MK6482 + Pembrolizumab + Lenvatinib), CTLA4 Triplet (MK1308A + Lenvatinib), Pembrolizumab/lenvatinib |
Biodrugs/ Drugs |
Cancer |
Pembrolizumab (MK-3475) in Combination with MK-6482 and Lenvatinib (MK-7902), or MK-1308A in Combination with Lenvatinib, versus Pembrolizumab and Lenvatinib, as First line Treatment in Participants with Advanced Clear Cell Renal Cell Carcinoma (ccRCC) |
3PhIII |
HIF Triplet (MK6482 + Pembrolizumab + Lenvatinib), CTLA4 Triplet (MK1308A + Lenvatinib), Pembrolizumab/lenvatinib
Therapeutic area:
Cancer
|
|
MSD |
Pembrolizumab / Olaparib |
Biodrugs/ Drugs |
Cancer |
Pembrolizumab in combination w/concurrent chemoradiation therapy followed by Pembrolizumab w/or w/o Olaparib,compared to concurrent chemoradiation therapy alone in participants w/newly diagnosed treatment-Naïve limited-Stage Small Cell Lung Cancer(LS-SCL |
3PhIII |
Pembrolizumab / Olaparib
Therapeutic area:
Cancer
|
|
MSD |
Zilovertamab Vedotin (MK2140) |
Biodrugs/ Drugs |
Cancer |
A Phase 2 Open-label Clinical Study to Evaluate the Efficacy and Safety of Zilovertamab Vedotin (MK-2140) in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma |
2PhII |
Zilovertamab Vedotin (MK2140)
Therapeutic area:
Cancer
|
|
MSD |
Pembrolizumab + Lenvatinibb |
Biodrugs/ Drugs |
Cancer |
Previously untreated advanced or metastatic nccRCC |
2PhII |
Pembrolizumab + Lenvatinibb
Therapeutic area:
Cancer
|
|
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
Adjuvant Therapy with Pembrolizumab Vs. Placebo in Resected Stage II Melanoma. |
3PhIII |
Pembrolizumab
Therapeutic area:
Cancer
|
|
MSD |
MK6482 + lenvatinib + Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
Multiple Solid Tumors |
2PhII |
MK6482 + lenvatinib + Pembrolizumab
Therapeutic area:
Cancer
|
|
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
Phase III extension study for participants with advanced tumors in pembrolizumab trials |
3PhIII |
Pembrolizumab
Therapeutic area:
Cancer
|
|
MSD |
Lenvatinib |
Biodrugs/ Drugs |
Cancer |
Children, Adolescents, and Young Adults with Relapsed or Refractory Solid Malignancies |
2PhII |
Lenvatinib
Therapeutic area:
Cancer
|
|
MSD |
Pembrolizumab/Lenvatinib |
Biodrugs/ Drugs |
Cancer |
Lenvatinib plus Pembrolizumab for Second Line Therapy of recurrent/metastatic head and neck squamous cell carcinoma have progressed after platinum therapy and post anti-PD1b inhibitor |
2PhII |
Pembrolizumab/Lenvatinib
Therapeutic area:
Cancer
|
|
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
Long-term Safety and Efficacy in Participants with Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab Trial |
3PhIII |
Pembrolizumab
Therapeutic area:
Cancer
|
|
MSD |
BET Inhibitor |
Biodrugs/ Drugs |
Cancer |
4 Select Advanced Solid Tumors |
1PhI |
BET Inhibitor
Therapeutic area:
Cancer
|
|
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
Study of Pembrolizumab/Epacadostat/ Chemotherapy in Metastatic Non-small Cell Lung Cancer. |
3PhIII |
Pembrolizumab
Therapeutic area:
Cancer
|
|
MSD |
Pembrolizumab/Olaparib |
Biodrugs/ Drugs |
Cancer |
Pembrolizumab/Chemotherapy Followed by Pembrolizumab and Maintenance Olaparib for non Squamous Non Small cell Lung cancer |
3PhIII |
Pembrolizumab/Olaparib
Therapeutic area:
Cancer
|
|
MSD |
MK1308A (quavonlimab+pembro) |
Biodrugs/ Drugs |
Cancer |
Multicenter,Multi Arm,Evaluate Pembrolizumab (MK-3475) or MK-1308A (Co-formulated quavonlimab (MK-1308)/pembrolizumab) in Participants w/Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Cancer: (MK-1308A-008) |
2PhII |
MK1308A (quavonlimab+pembro)
Therapeutic area:
Cancer
|
|
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
10 Select Advanced Solid Tumors |
1PhI |
Pembrolizumab
Therapeutic area:
Cancer
|
|
MSD |
Prevymis (Letermovir) |
Biodrugs/ Drugs |
Infections |
Prevention of CMV disease in D+/R- kidney transplant recipients |
3PhIII |
Prevymis (Letermovir)
Therapeutic area:
Infections
|
|
MSD |
Golimumab |
Biodrugs/ Drugs |
Autoimmune & Inflammation |
Non-radiographic axial Spondyloarthritis |
4Reg. |
Golimumab
Therapeutic area:
Autoimmune & Inflammation
|
|
MSD |
Pembrolizumab / Olaparib |
Biodrugs/ Drugs |
Cancer |
Study of Olaparib Plus Pembrolizumab versus Chemotherapy Plus Pembrolizumab after induction of Clinical Benefit With First-line Chemotherapy Plus Pembrolizumab in Participants with locally recurrent inoperable or Metastatic Triple Negative Breast Cancer |
2PhII |
Pembrolizumab / Olaparib
Therapeutic area:
Cancer
|
|
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
Carboplatin-Paclitaxel/Nab-Paclitaxel Chemotherapy with or without Pembrolizumab in First Line Metastatic Squamous Non-small Cell Lung Cancer Subjects. |
3PhIII |
Pembrolizumab
Therapeutic area:
Cancer
|
|
MSD |
ZINPLAVA |
Biodrugs/ Drugs |
Infections |
in Children Aged 1 to <18 Years Receiving Antibacterial Drug Treatment for C. difficile Infection (Toxin B) |
3PhIII |
ZINPLAVA
Therapeutic area:
Infections
|
|
MSD |
Pembrolizumab/Enfortumab |
Biodrugs/ Drugs |
Cancer |
Perioperative Pembrolizumab for Cis-Ineligible Muscle Invasive Bladder Cancer |
3PhIII |
Pembrolizumab/Enfortumab
Therapeutic area:
Cancer
|
|
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
Advanced Gastric or Gastroesophageal Junction Adenocarcinoma First line. |
3PhIII |
Pembrolizumab
Therapeutic area:
Cancer
|
|
MSD |
Nemtabrutinib |
Biodrugs/ Drugs |
Cancer |
A Phase 2 Study to Evaluate the Efficacy and Safety of MK-1026 in Participants with Hematologic Malignancies. |
2PhII |
Nemtabrutinib
Therapeutic area:
Cancer
|
|
MSD |
Pembrolizumab/Lenvatinib |
Biodrugs/ Drugs |
Cancer |
Lenvatinib in combination with Pembrolizumab in Participants with Metastatic Colorectal Cancer who have received and progressed on or after or became intolerant to prior treatment |
3PhIII |
Pembrolizumab/Lenvatinib
Therapeutic area:
Cancer
|
|
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
Trastuzumab + Chemotherapy with or without Pembrolizumab as First-line Treatment in Participants With HER2 Positive Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma |
3PhIII |
Pembrolizumab
Therapeutic area:
Cancer
|
|
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
First Line Study of Pembrolizumab +/- Ipilimumab in NSCLC |
3PhIII |
Pembrolizumab
Therapeutic area:
Cancer
|
|
MSD |
Pembrolizumab/Olaparib |
Biodrugs/ Drugs |
Cancer |
Phase III first line chemotherapy plus pembrolizumab + olaparib for BRCA non-mutated advanced EOC (epitelial ovarian cancer) |
3PhIII |
Pembrolizumab/Olaparib
Therapeutic area:
Cancer
|
|
MSD |
MK-1308A/Lenvatinib |
Biodrugs/ Drugs |
Cancer |
MK-1308A (Coformulated MK-1308/MK-3475), plus Lenvatinib (E7080/MK-7902) in First-line Therapy of Advanced Hepatocellular Carcinoma |
2PhII |
MK-1308A/Lenvatinib
Therapeutic area:
Cancer
|
|
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
Pembrolizumab in subjects with Hepatocellular Carcinoma and Complete Radiological Response after Surgical Resection or Local Ablation |
3PhIII |
Pembrolizumab
Therapeutic area:
Cancer
|
|
MSD |
Prevymis (Letermovir) |
Biodrugs/ Drugs |
Infections |
Pediatric participants from birth to less than 18 years of age at risk of developing CMV infection and/or disease following allogeneic haematopoietic stem cell transplantation (HSCT) |
2PhII |
Prevymis (Letermovir)
Therapeutic area:
Infections
|
|
MSD |
Gefapixant |
Biodrugs/ Drugs |
Respiratory and Pulmonary system |
Chronic cough |
3PhIII |
Gefapixant
Therapeutic area:
Respiratory and Pulmonary system
|
|
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
Chemoradiotherapy With or Without Pembrolizumab for the Treatment of High-risk, Locally Advanced Cervical Cancer |
3PhIII |
Pembrolizumab
Therapeutic area:
Cancer
|
|
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
Chemo +/- Pembrolizumab as Perioperative Therapy for Resectable Stage IIB or IIIA Non-small Cell Lung Cancer. |
3PhIII |
Pembrolizumab
Therapeutic area:
Cancer
|
|
MSD |
Pembrolizumab/Olaparib |
Biodrugs/ Drugs |
Cancer |
Pembrolizumab in combination w/concurrent chemoradiation therapy followed by Pembrolizumab w/or w/o Olaparib compared w/concurrent chemoradiation therapy followed by Durvalumab in participants w/unresectable,Locally Advanced,STIII Non-Small Cell Lung Canc |
3PhIII |
Pembrolizumab/Olaparib
Therapeutic area:
Cancer
|
|
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
Selected Advanced Solid Tumors. |
1PhI |
Pembrolizumab
Therapeutic area:
Cancer
|
|
MSD |
Anacetrapib |
Biodrugs/ Drugs |
Cardiovascular and circulatory systems |
Coronary Heart Disease (CHD) or CHD Risk- Equivalent Disease |
3PhIII |
Anacetrapib
Therapeutic area:
Cardiovascular and circulatory systems
|
|
MSD |
Pembrolizumab/Lenvatinib |
Biodrugs/ Drugs |
Cancer |
Lenvatinib plus Pembrolizumab for First Line Therapy of Advanced HCC |
3PhIII |
Pembrolizumab/Lenvatinib
Therapeutic area:
Cancer
|
|
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
Advanced Gastric or Gastroesophageal Junction Adenocarcinoma after First Line Progression |
3PhIII |
Pembrolizumab
Therapeutic area:
Cancer
|
|
MSD |
Olaparib |
Biodrugs/ Drugs |
Cancer |
"Olaparib vs Olaparib + Bevacizumab vs 5FU + Bevacizumab in metastasic colorectal cancer". |
3PhIII |
Olaparib
Therapeutic area:
Cancer
|
|
MSD |
Pembrolizumab/Lenvatinib |
Biodrugs/ Drugs |
Cancer |
Lenvatinib plus Pembrolizumab plus Chemotherapy for the Treatment of Advanced/Metastatic Gastroesophageal Adenocarcinoma |
3PhIII |
Pembrolizumab/Lenvatinib
Therapeutic area:
Cancer
|
|
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
Pembroluzimab given concomitantly with chemoradiation in subjects with locally advanced head and neck squamous cell carcinoma |
3PhIII |
Pembrolizumab
Therapeutic area:
Cancer
|
|
MSD |
Pembrolizumab/Olaparib |
Biodrugs/ Drugs |
Cancer |
Olaparib in combination with Pembrolizumab in Participants with solid tumors Previously Treated |
2PhII |
Pembrolizumab/Olaparib
Therapeutic area:
Cancer
|
|
MSD |
Vericiguat |
Biodrugs/ Drugs |
Cardiovascular and circulatory systems |
HFrEF - heart failure with reduced ejection fraction
(in colaboration with Roche) |
3PhIII |
Vericiguat
Therapeutic area:
Cardiovascular and circulatory systems
|
|
MSD |
MK1454/Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
Intratumoral MK-1454 plus Pembrolizumab First Line Metastatic or Unresectable, Recurrent Head and Neck Squamous Cell Carcinoma |
2PhII |
MK1454/Pembrolizumab
Therapeutic area:
Cancer
|
|
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
Pembrolizumab Versus Placebo as Adjuvant Therapy in High-risk Locally Advanced Cutaneous Squamous Cell Carcinoma |
3PhIII |
Pembrolizumab
Therapeutic area:
Cancer
|
|
MSD |
Prevymis (Letermovir) |
Biodrugs/ Drugs |
Infections |
Prevention of Clinically Significant Human Cytomegalovirus (CMV) Infection in Adult, CMV-Seropositive Allogeneic Hematopoietic Stem Cell Transplant Recipients |
3PhIII |
Prevymis (Letermovir)
Therapeutic area:
Infections
|
|
MSD |
Gardasil 9 |
Vaccines |
Infections |
9vHPV vaccine in adult males 20 to 45 years of age |
3PhIII |
Gardasil 9
Therapeutic area:
Infections
|
|
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
Subcutaneous Pembrolizumab versus Intravenous Pembrolizumab administrated with Platinum doublet chemotherapy in Metastasic Squamous or Nonsquamous non small cell lung cancer |
3PhIII |
Pembrolizumab
Therapeutic area:
Cancer
|
|
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
Chemotherapy with or without Pembrolizumab in TKI-resistant EGFR-mutated Tumors in Metastatic Non-Squamous Non-small Cell Lung Cancer. |
3PhIII |
Pembrolizumab
Therapeutic area:
Cancer
|
|
MSD |
Olaparib |
Biodrugs/ Drugs |
Cancer |
"Olaparib Monotherapy in Participants with Previously treated, Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced Cancer". |
2PhII |
Olaparib
Therapeutic area:
Cancer
|
|
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
Pembrolizumab or Placebo Plus Gemcitabine/Cisplatin for First-Line Advanced and/or Unresectable Biliary Tract Carcinoma |
3PhIII |
Pembrolizumab
Therapeutic area:
Cancer
|
|
MSD |
Pembrolizumab/Lenvatinib |
Biodrugs/ Drugs |
Cancer |
Pembrolizumab and lenvatinib in Combination with Transarterial Chemoembolization (TACE) Versus TACE in Participants with Incurable/Non-metastatic Hepatocellular Carcinoma |
3PhIII |
Pembrolizumab/Lenvatinib
Therapeutic area:
Cancer
|
|
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
First line treatment of recurrent/Metastasic Head and Neck Squamous Cell Carcinoma. |
3PhIII |
Pembrolizumab
Therapeutic area:
Cancer
|
|
MSD |
Pembrolizumab/Lenvatinib |
Biodrugs/ Drugs |
Cancer |
Pembrolizumab + lenvatinib por previously untreated advanced or metastatic nccRCC |
2PhII |
Pembrolizumab/Lenvatinib
Therapeutic area:
Cancer
|
|
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
Pembrolizumab in Previously Treated Subjects with Squamous Histology Non-Small Cell Lung Cancer |
3PhIII |
Pembrolizumab
Therapeutic area:
Cancer
|
|
MSD |
Pembrolizumab/Olaparib |
Biodrugs/ Drugs |
Cancer |
Olaparib in Combination with Pembrolizumab in Participants with Previously Treated, Homologous Recombination Repair Mutation (HRRm) and/or Homologous Recombination Deficiency (HRD)-Positive Advanced Cancer |
2PhII |
Pembrolizumab/Olaparib
Therapeutic area:
Cancer
|
|
MSD |
MK1308A , MK4280A, MK6482, MK4830, Pembrolizumab and Lenvatinib |
Biodrugs/ Drugs |
Cancer |
Umbrella trial Immune & Targeted Combin Therapies as 1st line treatm in RCC subj w/MK1308A+Lenva or MK4280A+Lenva or MK 6482+Pembro+Lenva vs Pembro+Lenva or as 2nd line & beyond treatm in RCC subj w/MK1308A or MK4280A or MK4830+Pembro or MK6482+Pembro+Len |
2PhII |
MK1308A , MK4280A, MK6482, MK4830, Pembrolizumab and Lenvatinib
Therapeutic area:
Cancer
|
|
MSD |
MK-3655 |
Biodrugs/ Drugs |
Digestive System |
MK-3655 in Individuals with Pre-Cirrhotic Nonalcoholic Steatohepatitis. |
2PhII |
MK-3655
Therapeutic area:
Digestive System
|
|
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
Pembrolizumab in advanced Merkel Cell Carcinoma (MCC) |
3PhIII |
Pembrolizumab
Therapeutic area:
Cancer
|
|
MSD |
RECARBRIO (mk7655A) |
Biodrugs/ Drugs |
Infections |
Pediatric Participants From Birth to Less Than 18 Years of Age With Confirmed or Suspected Gram-negative Bacterial Infection |
3PhIII |
RECARBRIO (mk7655A)
Therapeutic area:
Infections
|
|
MSD |
Gardasil 9 |
Vaccines |
Infections |
VPH in preadolescents and adolescents |
3PhIII |
Gardasil 9
Therapeutic area:
Infections
|
|
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
Adjuvant chemotherapy plus pembrolizumab/placebo for endometrial cancer after surgery with curative intent |
3PhIII |
Pembrolizumab
Therapeutic area:
Cancer
|
|
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
Lenalidomide and low dose dexamethasone with Pembrolizumab in Newly diagnosed and treated naive Multiple Myeloma. |
3PhIII |
Pembrolizumab
Therapeutic area:
Cancer
|
|
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
Pembrolizumab in First Line Metastatic Non-squamous Non-small Cell Lung Cancer Subjects. |
3PhIII |
Pembrolizumab
Therapeutic area:
Cancer
|
|
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
Pembrolizumab in Advanced Solid Tumors Analyzed for Predictive Biomarkers |
2PhII |
Pembrolizumab
Therapeutic area:
Cancer
|
|
MSD |
Pembrolizumab/Lenvatinib |
Biodrugs/ Drugs |
Cancer |
Lenvatinib plus Pembrolizumab in Previously Treated Subjects with Selected Solid Tumors |
2PhII |
Pembrolizumab/Lenvatinib
Therapeutic area:
Cancer
|
|
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
Neoadjuvant registration study -Triple negative breast cancer. |
3PhIII |
Pembrolizumab
Therapeutic area:
Cancer
|
|
MSD |
Pembrolizumab+ MK7684 (Vibostolimab) |
Biodrugs/ Drugs |
Cancer |
A Phase 2, Open-label Study to Evaluate the Safety and Efficacy of MK-7684A (MK-7684 [Vibostolimab] with MK-3475 [Pembrolizumab] Coformulation) in Participants with Relapsed or Refractory Hematological Malignancies |
2PhII |
Pembrolizumab+ MK7684 (Vibostolimab)
Therapeutic area:
Cancer
|
|
MSD |
Anacetrapib |
Biodrugs/ Drugs |
Metabolic / Endocrinology |
Coronary Heart Disease (CHD) or CHD Risk- Equivalent Disease |
3PhIII |
Anacetrapib
Therapeutic area:
Metabolic / Endocrinology
|
|
MSD |
Pembrolizumab/Lenvatinib |
Biodrugs/ Drugs |
Cancer |
Subjects with KRASG12C Mutant Advanced Solid Tumors |
1PhI |
Pembrolizumab/Lenvatinib
Therapeutic area:
Cancer
|
|
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
Advanced/Unresectable or Metastatic Bladder Cancer |
3PhIII |
Pembrolizumab
Therapeutic area:
Cancer
|
|
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
Pembrolizumab in Subjects with Metastatic Castration-Resistant Prostate Cancer (mCRPC) Previously Treated with Chemotherapy |
2PhII |
Pembrolizumab
Therapeutic area:
Cancer
|
|
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
Lenvatinib in Combination with Pembrolizumab Versus Treatment of Physician’s Choice in participants with Advanced Endometrial Cancer. |
3PhIII |
Pembrolizumab
Therapeutic area:
Cancer
|
|
MSD |
Pembrolizumab/Olaparib |
Biodrugs/ Drugs |
Cancer |
Pembro plus Olaparib Vs Abiraterone Acetate or Enzalutamide in participants w/metastatic castration-resistant prostate cancer who are unselected for homologous recomb repair defects & have failed prior treatm. w/one next-generation hormonal agent and chem |
3PhIII |
Pembrolizumab/Olaparib
Therapeutic area:
Cancer
|
|
MSD |
MK4280A (favezelimab+pembro) |
Biodrugs/ Drugs |
Cancer |
A Phase 3 study of MK-4280A [co-formulated favezelimab (MK-4280) plus pembrolizumab (MK-3475)] Versus Standard of Care in Previously Treated Metastatic PD-L1 positive Colorectal Cancer |
3PhIII |
MK4280A (favezelimab+pembro)
Therapeutic area:
Cancer
|
|
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
Pembrolizumab with or without Chemotherapy as First-line Treatment in Participants With HER2 negative Advanced Gastric or Gastroesophageal Junction Adenocarcinoma |
3PhIII |
Pembrolizumab
Therapeutic area:
Cancer
|
|
MSD |
RIG-I |
Biodrugs/ Drugs |
Cancer |
Advanced/Metastatic or Recurrent Solid Tumors |
1PhI |
RIG-I
Therapeutic area:
Cancer
|
|
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
"Pembrolizumab as Neoadjuvant Therapy and in Combination With Standard of Care as Adjuvant Therapy for Stage III-IVA Resectable Locoregionally Advanced Head and Neck Squamous Cell
Carcinoma (LA HNSCC)" |
3PhIII |
Pembrolizumab
Therapeutic area:
Cancer
|
|
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
Patients with a histologically confirmed diagnosis of melanoma (MEL) with unresectable or metastatic disease that have not received ipilimumab (IPI) treatment. |
3PhIII |
Pembrolizumab
Therapeutic area:
Cancer
|
|
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
Peri-operative Pembrolizumab + Neoadjuvant Chemotherapy vs. Placebo + Neoadjuvant Chemotherapy for Cis-Eligible Muscle Invasive Bladder Cancer |
3PhIII |
Pembrolizumab
Therapeutic area:
Cancer
|
|
MSD |
Pembrolizumab/Lenvatinib |
Biodrugs/ Drugs |
Cancer |
Lenvatinib plus Pembrolizumab for First Line Therapy of Advanced melanoma |
3PhIII |
Pembrolizumab/Lenvatinib
Therapeutic area:
Cancer
|
|
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
Pembrolizumab in combination with axitinib versus sunitinib monotherapy as a first-line treatment for advanced or metastatic clear-cell renal cell carcinoma. |
3PhIII |
Pembrolizumab
Therapeutic area:
Cancer
|
|
MSD |
Pembrolizumab+MK5890 o MK4830 o Lenvatinib + Etoposido/Platinum |
Biodrugs/ Drugs |
Cancer |
Platform trial: Pembrolizumab plus Investigational Agents in Combination with Etoposide and Cisplatin or CarboplatinThe first-line treatment of participants with extensive-stage small cell lung cancer |
2PhII |
Pembrolizumab+MK5890 o MK4830 o Lenvatinib + Etoposido/Platinum
Therapeutic area:
Cancer
|
|
MSD |
Favezelimab/Pembrolizumab/Lenvatinib |
Biodrugs/ Drugs |
Cancer |
MK-4280 as Monotherapy and in Combination with Pembrolizumab with or without Chemotherapy or Lenvatinib (E7080/MK-7902) in Subjects with Advanced Solid Tumor |
1PhI |
Favezelimab/Pembrolizumab/Lenvatinib
Therapeutic area:
Cancer
|
|
MSD |
Inactivated VZV Vaccine |
Vaccines |
Cancer |
Adult Patients with Solid Tumor or Hematologic Malignancy |
3PhIII |
Inactivated VZV Vaccine
Therapeutic area:
Cancer
|
|
MSD |
Pembrolizumab/Lenvatinib/Belzutifan |
Biodrugs/ Drugs |
Cancer |
Pembrolizumab Plus Lenvatinib in combination with Belzutifan in solid tumors |
2PhII |
Pembrolizumab/Lenvatinib/Belzutifan
Therapeutic area:
Cancer
|
|
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
Pembrolizumab in Advanced Renal Cell Carcinoma (RCC) |
2PhII |
Pembrolizumab
Therapeutic area:
Cancer
|
|
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
Pembrolizumab in Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (mCRPC) |
2PhII |
Pembrolizumab
Therapeutic area:
Cancer
|
|
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
Pembrolizumab (MK-3475) Evaluating Predictive Biomarkers in Subjects with Advanced Solid Tumors |
2PhII |
Pembrolizumab
Therapeutic area:
Cancer
|
|
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
Pembrolizumab in Combination with Cisplatin and 5-Fluorouracil as First Line treatment in Subjects with Advanced/Metastatic Esophageal Carcinoma. |
3PhIII |
Pembrolizumab
Therapeutic area:
Cancer
|
|
MSD |
MK4830 |
Biodrugs/ Drugs |
Cancer |
MK-4830 as Monotherapy and in Combination with Pembrolizumab for Participants with Advanced Solid tumors |
1PhI |
MK4830
Therapeutic area:
Cancer
|
|
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
Pembrolizumab + Chemotherapy + Radiotherapy in Stage III NSCLC |
2PhII |
Pembrolizumab
Therapeutic area:
Cancer
|
|
MSD |
V-937/Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
Clinical Study of Intratumoral Administration of V937 in Combination with Pembrolizumab (MK-3475) in Participants with Advanced/Metastatic Solid Tumors |
2PhII |
V-937/Pembrolizumab
Therapeutic area:
Cancer
|
|
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
Recurrent or Progressive Metastatic Bladder Cancer. |
3PhIII |
Pembrolizumab
Therapeutic area:
Cancer
|
|
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
Pembrolizumab in Combination With Chemoradiotherapy (CRT) versus CRT Alone in Participants with Muscle Invasive Bladder Cancer |
3PhIII |
Pembrolizumab
Therapeutic area:
Cancer
|
|
MSD |
Pembrolizumab/Lenvatinib |
Biodrugs/ Drugs |
Cancer |
Lenvatinib plus Pembrolizumab for Second Line Therapy of Advanced melanoma post anti-PD1b inhibitor |
2PhII |
Pembrolizumab/Lenvatinib
Therapeutic area:
Cancer
|
|
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
PD-L1 Strong Metastatic Non-Small Cell Lung Cancer |
3PhIII |
Pembrolizumab
Therapeutic area:
Cancer
|
|
MSD |
pembrolizumab+MK6482+lenvatinib / MK1308A + lenvatinib |
Biodrugs/ Drugs |
Cancer |
Pembrolizumab (in Combination with MK-6482 and Lenvatinib, or MK-1308A in Combination with Lenvatinib, versus Pembrolizumab and Lenvatinib, as First-line Treatment for ccRCC |
3PhIII |
pembrolizumab+MK6482+lenvatinib / MK1308A + lenvatinib
Therapeutic area:
Cancer
|
|
MSD |
Doravirine |
Biodrugs/ Drugs |
Infections |
HIV Infection |
3PhIII |
Doravirine
Therapeutic area:
Infections
|
|
MSD |
MK 3475/Pembrolizumab +MK5890/MK4830/Lenvatinib + Etoposide/Platinum |
Biodrugs/ Drugs |
Cancer |
Platform trial: To Evaluate the Efficacy and Safety of Pembrolizumab plus Investigational Agents in Combination w/Etoposide and Cisplatin or Carboplatin for the First-Line Treatment of Participants w/Extensive-Stage Small Cell Lung Cancer (KEYNOTE-B99) |
2PhII |
MK 3475/Pembrolizumab +MK5890/MK4830/Lenvatinib + Etoposide/Platinum
Therapeutic area:
Cancer
|
|
MSD |
Pembrolizumab/MK1308 or MK1308 + Lenvatinib or MK1308 + MK4830 or MK4280 |
Biodrugs/ Drugs |
Cancer |
Platform trial: Pembrolizumab in combination with Investigational Agents in PD-1/L1-refactory Extensive stage small cell lung Cancer in need of second-line therapy. |
2PhII |
Pembrolizumab/MK1308 or MK1308 + Lenvatinib or MK1308 + MK4830 or MK4280
Therapeutic area:
Cancer
|
|
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
Pembrolizumab vs chemotherapy in patients with advanced melanoma. |
2PhII |
Pembrolizumab
Therapeutic area:
Cancer
|
|
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
MSI-H or dMMR Stage IV Colorectal Carcinoma treatment naïve |
3PhIII |
Pembrolizumab
Therapeutic area:
Cancer
|
|
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
Pembrolizumab via Subcutaneous Injection of MK-3475A, a Formulation of Pembrolizumab With MK-5180, in Participants with Advanced Solid Tumors. |
1PhI |
Pembrolizumab
Therapeutic area:
Cancer
|
|
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have progressed after First Line Standard Therapy. |
3PhIII |
Pembrolizumab
Therapeutic area:
Cancer
|
|
MSD |
MK-5890/Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
Selected Advanced Solid Tumors |
1PhI |
MK-5890/Pembrolizumab
Therapeutic area:
Cancer
|
|
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
Stereotactic Body Radiotherapy (SBRT) with Pembrolizumab or Placebo |
3PhIII |
Pembrolizumab
Therapeutic area:
Cancer
|
|
MSD |
Vaxelis |
Vaccines |
Infections |
Vaccination against diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis, and invasive diseases caused by Haemophilus influenzae type b (Paediatric population) |
3PhIII |
Vaxelis
Therapeutic area:
Infections
|
|
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
Subjects with histologically confirmed diagnosis of melanoma with unresectable or metastatic melanoma. |
3PhIII |
Pembrolizumab
Therapeutic area:
Cancer
|
|
MSD |
Pembrolizumab/MK-7684 |
Biodrugs/ Drugs |
Cancer |
Basket study of MK-7684A, a Co formation of Vibostolimab (MK-7684) with Pembrolizumab (MK-3475), with or without other anticancer therapies in participants with selected solid tumors |
2PhII |
Pembrolizumab/MK-7684
Therapeutic area:
Cancer
|
|
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
Pembrolizumab Plus Enzalutamide versus Placebo Plus Enzalutamide in Participants with metastatic Castration-Resistant Prostate Cancer |
3PhIII |
Pembrolizumab
Therapeutic area:
Cancer
|
|
MSD |
Pembrolizumab/Lenvatinib |
Biodrugs/ Drugs |
Cancer |
Pemetrexed + Platinum Chemotherapy + Pembrolizumab with or without Lenvatinib in first line (1L) metastatic non-squamous NSCLC |
3PhIII |
Pembrolizumab/Lenvatinib
Therapeutic area:
Cancer
|
|
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
1st Line mTNBC choice of Taxane +/- Pembro-Triple negative breast cancer |
3PhIII |
Pembrolizumab
Therapeutic area:
Cancer
|
|
MSD |
Pembrolizumanb/Enfortumab |
Biodrugs/ Drugs |
Cancer |
Perioperative EV + Pembrolizumab vs Neoadjuvant Chemotherapy for Cisplatin-eligible Muscle Invasive Bladder Cancer |
3PhIII |
Pembrolizumanb/Enfortumab
Therapeutic area:
Cancer
|
|
MSD |
CAVATAK/Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
Study of ITu V937 in Combination with Pembrolizumab selected solid tumors |
2PhII |
CAVATAK/Pembrolizumab
Therapeutic area:
Cancer
|
|
MSD |
MK6482 + pembrolizumam / pembrolizumab + placebo |
Biodrugs/ Drugs |
Cancer |
Pembrolizumab + belzutifan vs pembrolizumab + placebo in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy |
3PhIII |
MK6482 + pembrolizumam / pembrolizumab + placebo
Therapeutic area:
Cancer
|
|
MSD |
Pembrolizumab/MK-7684 |
Biodrugs/ Drugs |
Cancer |
Pembrolizumab in combination with anti-TIGIT or Pembrolizumab in combination with anti-TIGIT plus Docetaxel in metastasic non small lung cancer with progressive disease after treatment with a platinum doublet chemotherapy or immunotheraphy |
2PhII |
Pembrolizumab/MK-7684
Therapeutic area:
Cancer
|
|
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
MSI-H or dMMR Stage IV Colorectal Carcinoma (after progression of First and second line Standard Therapy) |
2PhII |
Pembrolizumab
Therapeutic area:
Cancer
|
|
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
Pembrolizumab in recurrent or metastatic cutaneous squamous cell carcinoma |
2PhII |
Pembrolizumab
Therapeutic area:
Cancer
|
|
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
Phase 2 study of pembrolizumab and chemotherapy in patients with newly diagnosed classical Hodgkin Lymphoma |
2PhII |
Pembrolizumab
Therapeutic area:
Cancer
|
|
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
Pembrolizumab as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy. |
3PhIII |
Pembrolizumab
Therapeutic area:
Cancer
|
|
MSD |
MK6482 |
Biodrugs/ Drugs |
Cancer |
MK-6482 Versus Everolimus in Participants With Advanced Renal Cell Carcinoma That has Progressed After Prior PD-1/L1 and VEGF-Targeted Therapies. |
3PhIII |
MK6482
Therapeutic area:
Cancer
|
|
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
Neoadjuvant treatment Platinum Doublet Chemotherapy +/- Pembrolizumab followed by Surgery. |
3PhIII |
Pembrolizumab
Therapeutic area:
Cancer
|
|
MSD |
ZERBAXA |
Biodrugs/ Drugs |
Infections |
Pediatric participants with nosocomial pneumonia (HABP/VABP) |
1PhI |
ZERBAXA
Therapeutic area:
Infections
|
|
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
Pembrolizumab versus standard Treatment in subjects with recurrent or metastatic Head and Neck Cancer |
3PhIII |
Pembrolizumab
Therapeutic area:
Cancer
|
|
MSD |
Anti CTLA-4/Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
MK-1308 in Combination with Pembrolizumab vs MK1308 alone in Subjects with Advanced Solid Tumors (Melanoma Expansion Phase) |
2PhII |
Anti CTLA-4/Pembrolizumab
Therapeutic area:
Cancer
|
|
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
Metastatic Triple-Negative Breast Cancer (mTNBC). |
3PhIII |
Pembrolizumab
Therapeutic area:
Cancer
|
|
MSD |
Pembrolizumab/MK-7684 or MK-4830 or MK-5890 or MK-0482 |
Biodrugs/ Drugs |
Cancer |
KEYMAKER-U01 Master study: A phase 2, Umbrella study with Rolling Arms of Investigational Agents with either Pembrolizumab in combination with Chemotherapy or with Pembrolizumab alone in Patients with Advanced Non-small cell lung cancer (NSCLC) |
2PhII |
Pembrolizumab/MK-7684 or MK-4830 or MK-5890 or MK-0482
Therapeutic area:
Cancer
|
|
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
Pembrolizumab Plus Docetaxel versus Placebo Plus Docetaxel in Patients with Chemotherapy-Naïve metastatic Castration-Resistant Prostate Cancer |
3PhIII |
Pembrolizumab
Therapeutic area:
Cancer
|
|
MSD |
Pembrolizumab/Lenvatinib |
Biodrugs/ Drugs |
Cancer |
Pembrolizumab + lenvatinib versus docetaxel for metastatic NSCLC after platinum doublet chemotherapy and immunotherapy |
3PhIII |
Pembrolizumab/Lenvatinib
Therapeutic area:
Cancer
|
|
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
Pembrolizumab in children and young adults with newly diagnosed Classical Hodgkin Lymphoma |
2PhII |
Pembrolizumab
Therapeutic area:
Cancer
|
|
MSD |
Pneumococcal vaccine polyvalent |
Vaccines |
Infections |
Pedriatric Prevention of pneumococal infection with V114 |
3PhIII |
Pneumococcal vaccine polyvalent
Therapeutic area:
Infections
|
|
MSD |
Islatravir |
Biodrugs/ Drugs |
Infections |
HIV Infection |
3PhIII |
Islatravir
Therapeutic area:
Infections
|
|
MSD |
CAVATAK/Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
V937 in Combination with Pembrolizumab Versus Pembrolizumab Alone in Participants with Advanced/Metastatic Melanoma |
2PhII |
CAVATAK/Pembrolizumab
Therapeutic area:
Cancer
|
|
MSD |
Molnupiravir |
Biodrugs/ Drugs |
Infections
Respiratory and Pulmonary system |
Molnupiravir in non-hospitalized patients with COVID-19 |
3PhIII |
Molnupiravir
Therapeutic area:
Infections / Respiratory and Pulmonary system
|
|
MSD |
ZERBAXA |
Biodrugs/ Drugs |
Infections |
Pediatric Subjects with Complicated Intra-Abdominal Infection |
2PhII |
ZERBAXA
Therapeutic area:
Infections
|
|
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
1L dMMR Endometrial Carcinoma |
3PhIII |
Pembrolizumab
Therapeutic area:
Cancer
|
|
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
Progressive or recurrent Intermediate or High risk, Non-muscle invasive bladder Cancer |
3PhIII |
Pembrolizumab
Therapeutic area:
Cancer
|
|
MSD |
MK1084 + Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
A Phase 1 Study with MK-1084 as Monotherapy and in Combination with Pembrolizumab in Subjects with KRASG12C Mutant Advanced Solid Tumors |
1PhI |
MK1084 + Pembrolizumab
Therapeutic area:
Cancer
|
|
MSD |
MK6482 |
Biodrugs/ Drugs |
Cancer |
MK-6482 Monotherapy in Participants With Advanced Pheochromocytoma/Paraganglioma (PPGL) and Pancreatic Neuroendocrine Tumor (pNET) |
2PhII |
MK6482
Therapeutic area:
Cancer
|
|
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
Phase II, Pembrolizumab combined with chemotherapy as a First line treatment for NSCLC. |
2PhII |
Pembrolizumab
Therapeutic area:
Cancer
|
|
MSD |
MK0482 |
Biodrugs/ Drugs |
Cancer |
MK-0482 as Monotherapy and in Combination with Pembrolizumab for Participants with Advanced Solid tumors |
1PhI |
MK0482
Therapeutic area:
Cancer
|
|
MSD |
Pembrolizumab/Lenvatinib |
Biodrugs/ Drugs |
Cancer |
Phase III Pembrolizumab Plus Lenvatinib Versus Chemotherapy for the First-line Treatment of Persistent, Recurrent or Metastatic Endometrial Carcinoma |
3PhIII |
Pembrolizumab/Lenvatinib
Therapeutic area:
Cancer
|
|
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
ER+Neoadjuvant -Breast-Oestrogen receptor positive breast cancer |
3PhIII |
Pembrolizumab
Therapeutic area:
Cancer
|
|
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
First line study of pembrolizumab +/- epacadostat in NSCLC. |
2PhII |
Pembrolizumab
Therapeutic area:
Cancer
|
|
MSD |
RSV vaccine |
Biodrugs/ Drugs |
Infections |
VRS prevention in preterm and risk infants |
3PhIII |
RSV vaccine
Therapeutic area:
Infections
|
|
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
Pembrolizumab or Placebo Plus Enzalutamide/ADT in subjects with Metastatic Hormono-Senmsitive Prostate Cancer (mHSPC) |
3PhIII |
Pembrolizumab
Therapeutic area:
Cancer
|
|
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
20 Select Advanced Solid Tumors |
1PhI |
Pembrolizumab
Therapeutic area:
Cancer
|
|
MSD |
Posaconazole |
Biodrugs/ Drugs |
Infections |
Posaconazole for the treatment of invasive aspergillosis in adults and adolescents. |
3PhIII |
Posaconazole
Therapeutic area:
Infections
|
|
MSD |
Inactivated VZV Vaccine |
Vaccines |
Blood and Lymphatic systems |
Adult Patients with Solid Tumor or Hematologic Malignancy |
3PhIII |
Inactivated VZV Vaccine
Therapeutic area:
Blood and Lymphatic systems
|
|
MSD |
Molnupiravir |
Biodrugs/ Drugs |
Infections
Respiratory and Pulmonary system |
Molnupiravir in adults residing with a person with COVD-19 |
3PhIII |
Molnupiravir
Therapeutic area:
Infections / Respiratory and Pulmonary system
|
|
MSD |
ZERBAXA |
Biodrugs/ Drugs |
Respiratory and Pulmonary system |
Assess the Plasma Pharmacokinetics and Lung Penetration of Intravenous (IV) Ceftolozane/Tazobactam in Critically Ill Patients |
1PhI |
ZERBAXA
Therapeutic area:
Respiratory and Pulmonary system
|
|
MSD |
Pembrolizumab /7684A |
Biodrugs/ Drugs |
Cancer |
Study of MK-7684A plus Chemotherapy versus Pembrolizumab plus Chemotherapy as First Line Treatment for Participants With Metastatic Non-Small Cell Lung Cancer |
3PhIII |
Pembrolizumab /7684A
Therapeutic area:
Cancer
|
|
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
Pembrolizumab plus Epacadostat vs SOC (Sunitinib or Pazopanib) as First-Line Treatment for Locally Advanced or Metastatic Renal Cell Carcinoma |
3PhIII |
Pembrolizumab
Therapeutic area:
Cancer
|
|
MSD |
MK6482 + lenvatinib / cabozantinib |
Biodrugs/ Drugs |
Cancer |
MK-6482 in Combination with Lenvatinib (MK-7902) vs Cabozantinib for Second-line or Third-line Treatment in Participants with Advanced Renal Cell Carcinoma Who Have Progressed After Prior Anti-PD-1/L1 Therapy. |
3PhIII |
MK6482 + lenvatinib / cabozantinib
Therapeutic area:
Cancer
|
|
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
Phase III Pembro + Chemotherapy in Persistent, Recurrent or Metastatic Cervical Cancer |
3PhIII |
Pembrolizumab
Therapeutic area:
Cancer
|
|
MSD |
Mavezelimab/Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
4 Select Advanced Solid Tumors |
1PhI |
Mavezelimab/Pembrolizumab
Therapeutic area:
Cancer
|
 |
Novo Nordisk Pharma |
IDegLira (combination insulin degludec + liraglutide) |
Biodrugs/ Drugs |
Metabolic / Endocrinology |
Diabetes type 2 |
4Reg. |
IDegLira (combination insulin degludec + liraglutide)
Therapeutic area:
Metabolic / Endocrinology
|
|
Novo Nordisk Pharma |
Concizumab |
Biodrugs/ Drugs |
Blood and Lymphatic systems |
Haemophilia A and B |
2PhII |
Concizumab
Therapeutic area:
Blood and Lymphatic systems
|
|
Novo Nordisk Pharma |
Liraglutide 3mg |
Biodrugs/ Drugs |
Metabolic / Endocrinology |
Obesity |
4Reg. |
Liraglutide 3mg
Therapeutic area:
Metabolic / Endocrinology
|
|
Novo Nordisk Pharma |
Turoctocog alfa |
Biodrugs/ Drugs |
Blood and Lymphatic systems |
Haemophilia A |
4Reg. |
Turoctocog alfa
Therapeutic area:
Blood and Lymphatic systems
|
|
Novo Nordisk Pharma |
Semaglutide |
Biodrugs/ Drugs |
Metabolic / Endocrinology |
Diabetes type 2 |
3PhIII |
Semaglutide
Therapeutic area:
Metabolic / Endocrinology
|
|
Novo Nordisk Pharma |
Liraglutide |
Biodrugs/ Drugs |
Metabolic / Endocrinology |
Diabetes type 2 in paediatric population |
3PhIII |
Liraglutide
Therapeutic area:
Metabolic / Endocrinology
|
|
Novo Nordisk Pharma |
Nonacog beta pegol |
Biodrugs/ Drugs |
Blood and Lymphatic systems |
Haemophilia B |
4Reg. |
Nonacog beta pegol
Therapeutic area:
Blood and Lymphatic systems
|
|
Novo Nordisk Pharma |
N8-GP (glycopegylated recombinant FVIII) |
Biodrugs/ Drugs |
Blood and Lymphatic systems |
Haemophilia A |
3PhIII |
N8-GP (glycopegylated recombinant FVIII)
Therapeutic area:
Blood and Lymphatic systems
|
|
Novo Nordisk Pharma |
Faster-acting insulin aspart (FIAsp) |
Biodrugs/ Drugs |
Metabolic / Endocrinology |
Diabetes type 1 and type 2 |
4Reg. |
Faster-acting insulin aspart (FIAsp)
Therapeutic area:
Metabolic / Endocrinology
|
|
Novo Nordisk Pharma |
Monoclonal antibody anti Il-21 |
Biodrugs/ Drugs |
Metabolic / Endocrinology |
Diabetes type 1 |
2PhII |
Monoclonal antibody anti Il-21
Therapeutic area:
Metabolic / Endocrinology
|
|
Novo Nordisk Pharma |
Somapacitan(Long-acting growth hormone) |
Biodrugs/ Drugs |
Metabolic / Endocrinology |
Growth hormone deficiency |
3PhIII |
Somapacitan(Long-acting growth hormone)
Therapeutic area:
Metabolic / Endocrinology
|
|
Novo Nordisk Pharma |
IDegAsp (combination insulin degludec + insulin aspart) |
Biodrugs/ Drugs |
Metabolic / Endocrinology |
Diabetes type 2 and type 1 |
4Reg. |
IDegAsp (combination insulin degludec + insulin aspart)
Therapeutic area:
Metabolic / Endocrinology
|
|
Novo Nordisk Pharma |
Oral semaglutide |
Biodrugs/ Drugs |
Metabolic / Endocrinology |
Diabetes type 2 |
3PhIII |
Oral semaglutide
Therapeutic area:
Metabolic / Endocrinology
|
 |
Roche |
IPATASERTIB |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasms |
1PhI |
IPATASERTIB
Therapeutic area:
Cancer
|
|
Roche |
IPATASERTIB |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasm of prostate |
2PhII |
IPATASERTIB
Therapeutic area:
Cancer
|
|
Roche |
PERJETA |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasm of stomach |
3PhIII |
PERJETA
Therapeutic area:
Cancer
|
|
Roche |
CIF MEK INH |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasms |
1PhI |
CIF MEK INH
Therapeutic area:
Cancer
|
|
Roche |
SEMBRAGILINE |
Biodrugs/ Drugs |
Central Nervous System |
Alzheimer's disease |
2PhII |
SEMBRAGILINE
Therapeutic area:
Central Nervous System
|
|
Roche |
NEORECORMON |
Biodrugs/ Drugs |
Blood and Lymphatic systems |
Anaemia in neoplastic disease |
2PhII |
NEORECORMON
Therapeutic area:
Blood and Lymphatic systems
|
|
Roche |
OCRELIZUMAB |
Biodrugs/ Drugs |
Central Nervous System |
Musculoskeletal Disorders |
3PhIII |
OCRELIZUMAB
Therapeutic area:
Central Nervous System
|
|
Roche |
MABTHERA |
Biodrugs/ Drugs |
Blood and Lymphatic systems
Cancer |
Diffuse non-Hodgkin's lymphoma, unspecified |
3PhIII |
MABTHERA
Therapeutic area:
Blood and Lymphatic systems / Cancer
|
|
Roche |
EM ACTEMAB RA |
Biodrugs/ Drugs |
Autoimmune & Inflammation
Musculoskeletal Disorders |
Rheumatoid arthritis |
2PhII |
EM ACTEMAB RA
Therapeutic area:
Autoimmune & Inflammation / Musculoskeletal Disorders
|
|
Roche |
KADCYLA |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasm of breast |
3PhIII |
KADCYLA
Therapeutic area:
Cancer
|
|
Roche |
APITOLISIB |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasm without specification of site |
1PhI |
APITOLISIB
Therapeutic area:
Cancer
|
|
Roche |
LUMRETUZUMAB |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasm of breast |
1PhI |
LUMRETUZUMAB
Therapeutic area:
Cancer
|
|
Roche |
IPATASERTIB |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasm of stomach |
2PhII |
IPATASERTIB
Therapeutic area:
Cancer
|
|
Roche |
TASELISIB |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasm of breast |
3PhIII |
TASELISIB
Therapeutic area:
Cancer
|
|
Roche |
EM MS BIOMARKER |
Biodrugs/ Drugs |
Autoimmune & Inflammation
Digestive System |
Crohn's disease |
1PhI |
EM MS BIOMARKER
Therapeutic area:
Autoimmune & Inflammation / Digestive System
|
|
Roche |
VANUCIZUMAB |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasm of colon/rectum |
2PhII |
VANUCIZUMAB
Therapeutic area:
Cancer
|
|
Roche |
KADCYLA |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasm of stomach |
3PhIII |
KADCYLA
Therapeutic area:
Cancer
|
|
Roche |
PATECLIZUMAB |
Biodrugs/ Drugs |
Autoimmune & Inflammation
Musculoskeletal Disorders |
Rheumatoid arthritis |
2PhII |
PATECLIZUMAB
Therapeutic area:
Autoimmune & Inflammation / Musculoskeletal Disorders
|
|
Roche |
MABTHERA |
Biodrugs/ Drugs |
Blood and Lymphatic systems
Cancer |
Lymphoid leukaemia |
3PhIII |
MABTHERA
Therapeutic area:
Blood and Lymphatic systems / Cancer
|
|
Roche |
GAZYVA |
Biodrugs/ Drugs |
Blood and Lymphatic systems
Cancer |
Lymphoid leukaemia |
2PhII |
GAZYVA
Therapeutic area:
Blood and Lymphatic systems / Cancer
|
|
Roche |
APITOLISIB |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasms |
1PhI |
APITOLISIB
Therapeutic area:
Cancer
|
|
Roche |
LUMRETUZUMAB |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasm of bronchus and lung |
1PhI |
LUMRETUZUMAB
Therapeutic area:
Cancer
|
|
Roche |
KADCYLA |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasm of bronchus and lung |
2PhII |
KADCYLA
Therapeutic area:
Cancer
|
|
Roche |
VENETOCLAX |
Biodrugs/ Drugs |
Blood and Lymphatic systems
Cancer |
Lymphoid leukaemia |
3PhIII |
VENETOCLAX
Therapeutic area:
Blood and Lymphatic systems / Cancer
|
|
Roche |
LIFASTUZUMAB VEDOTIN |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasm of bronchus and lung |
1PhI |
LIFASTUZUMAB VEDOTIN
Therapeutic area:
Cancer
|
|
Roche |
ALEGLITAZAR |
Biodrugs/ Drugs |
Cardiovascular and circulatory systems
Metabolic / Endocrinology |
Atherosclerosis |
3PhIII |
ALEGLITAZAR
Therapeutic area:
Cardiovascular and circulatory systems / Metabolic / Endocrinology
|
|
Roche |
ALPHA7 NIC AGO |
Biodrugs/ Drugs |
Central Nervous System |
Alzheimer's disease |
2PhII |
ALPHA7 NIC AGO
Therapeutic area:
Central Nervous System
|
|
Roche |
OCRELIZUMAB |
Biodrugs/ Drugs |
Autoimmune & Inflammation
Musculoskeletal Disorders |
Rheumatoid arthritis |
3PhIII |
OCRELIZUMAB
Therapeutic area:
Autoimmune & Inflammation / Musculoskeletal Disorders
|
|
Roche |
POLATUZUMAB VEDOTIN |
Biodrugs/ Drugs |
Blood and Lymphatic systems
Cancer |
Follicular (nodular) non-Hodgkin's lymphoma |
2PhII |
POLATUZUMAB VEDOTIN
Therapeutic area:
Blood and Lymphatic systems / Cancer
|
|
Roche |
MABTHERA |
Biodrugs/ Drugs |
Blood and Lymphatic systems
Cancer |
Other + unspecif. types of non-Hodgkin's lymphoma |
3PhIII |
MABTHERA
Therapeutic area:
Blood and Lymphatic systems / Cancer
|
|
Roche |
GAZYVA |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasm of other and unspecified parts of biliary tract |
3PhIII |
GAZYVA
Therapeutic area:
Cancer
|
|
Roche |
BRAF KIN INH (2) |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasm without specification of site |
1PhI |
BRAF KIN INH (2)
Therapeutic area:
Cancer
|
|
Roche |
LUMRETUZUMAB |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasm without specification of site |
1PhI |
LUMRETUZUMAB
Therapeutic area:
Cancer
|
|
Roche |
LEBRIKIZUMAB |
Biodrugs/ Drugs |
Respiratory and Pulmonary system |
Other diseases of upper respiratory tract |
2PhII |
LEBRIKIZUMAB
Therapeutic area:
Respiratory and Pulmonary system
|
|
Roche |
XOLAIR |
Biodrugs/ Drugs |
Autoimmune & Inflammation
Dermatology |
Dermatitis (Allergic Contact) |
3PhIII |
XOLAIR
Therapeutic area:
Autoimmune & Inflammation / Dermatology
|
|
Roche |
OX40 |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasms |
1PhI |
OX40
Therapeutic area:
Cancer
|
|
Roche |
ALEGLITAZAR |
Biodrugs/ Drugs |
Metabolic / Endocrinology |
Diabetes Mellitus |
3PhIII |
ALEGLITAZAR
Therapeutic area:
Metabolic / Endocrinology
|
|
Roche |
ANTI-INFLUENZA A |
Biodrugs/ Drugs |
Infections |
Influenza |
2PhII |
ANTI-INFLUENZA A
Therapeutic area:
Infections
|
|
Roche |
OCRELIZUMAB |
Biodrugs/ Drugs |
Autoimmune & Inflammation
Musculoskeletal Disorders |
Systemic lupus erythematosus |
3PhIII |
OCRELIZUMAB
Therapeutic area:
Autoimmune & Inflammation / Musculoskeletal Disorders
|
|
Roche |
TARCEVA |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasm of other and ill-defined sites |
2PhII |
TARCEVA
Therapeutic area:
Cancer
|
|
Roche |
PEGASYS |
Biodrugs/ Drugs |
Infections |
Chronic viral haepatitis |
3PhIII |
PEGASYS
Therapeutic area:
Infections
|
|
Roche |
GPC3 MAB |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasm of liver |
2PhII |
GPC3 MAB
Therapeutic area:
Cancer
|
|
Roche |
CEA IL2V |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasms |
1PhI |
CEA IL2V
Therapeutic area:
Cancer
|
|
Roche |
PDL1 MAB |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasm without specification of site |
1PhI |
PDL1 MAB
Therapeutic area:
Cancer
|
|
Roche |
MERICITABINE |
Biodrugs/ Drugs |
Infections |
Chronic viral haepatitis |
2PhII |
MERICITABINE
Therapeutic area:
Infections
|
|
Roche |
ACTEMRA |
Biodrugs/ Drugs |
Autoimmune & Inflammation |
Other disorders involving the immune mechanism |
3PhIII |
ACTEMRA
Therapeutic area:
Autoimmune & Inflammation
|
|
Roche |
AVASTIN |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasm of cervix uteri |
2PhII |
AVASTIN
Therapeutic area:
Cancer
|
|
Roche |
AVASTIN |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasm of stomach |
3PhIII |
AVASTIN
Therapeutic area:
Cancer
|
|
Roche |
APITOLISIB |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasm of kidney except renal pelvis |
2PhII |
APITOLISIB
Therapeutic area:
Cancer
|
|
Roche |
PLGF MAB |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasm without specification of site |
1PhI |
PLGF MAB
Therapeutic area:
Cancer
|
|
Roche |
COBIMETINIB |
Biodrugs/ Drugs |
Cancer |
Malignant melanoma of skin |
3PhIII |
COBIMETINIB
Therapeutic area:
Cancer
|
|
Roche |
TAMIFLU |
Biodrugs/ Drugs |
Infections |
Influenza |
1PhI |
TAMIFLU
Therapeutic area:
Infections
|
|
Roche |
HPV16 TI |
Biodrugs/ Drugs |
Infections |
Viral agents as cause of diseases classified to other |
2PhII |
HPV16 TI
Therapeutic area:
Infections
|
|
Roche |
PDL1 MAB |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasm of bronchus and lung |
3PhIII |
PDL1 MAB
Therapeutic area:
Cancer
|
|
Roche |
TARCEVA |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasm of pancreas |
2PhII |
TARCEVA
Therapeutic area:
Cancer
|
|
Roche |
ACTEMRA |
Biodrugs/ Drugs |
Cardiovascular and circulatory systems |
Peripheral Vascular Diseases |
3PhIII |
ACTEMRA
Therapeutic area:
Cardiovascular and circulatory systems
|
|
Roche |
COBIMETINIB |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasm without specification of site |
1PhI |
COBIMETINIB
Therapeutic area:
Cancer
|
|
Roche |
PDL1 MAB |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasms |
1PhI |
PDL1 MAB
Therapeutic area:
Cancer
|
|
Roche |
ONARTUZUMAB |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasm of brain |
2PhII |
ONARTUZUMAB
Therapeutic area:
Cancer
|
|
Roche |
ERIVEDGE |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasm of other and ill-defined sites |
2PhII |
ERIVEDGE
Therapeutic area:
Cancer
|
|
Roche |
DALCETRAPIB |
Biodrugs/ Drugs |
Cardiovascular and circulatory systems |
Acute myocardial infarction |
3PhIII |
DALCETRAPIB
Therapeutic area:
Cardiovascular and circulatory systems
|
|
Roche |
BASIMGLURANT |
Biodrugs/ Drugs |
Genetic Diseases and Dysmorphic syndromes |
Fragile X Syndrome |
2PhII |
BASIMGLURANT
Therapeutic area:
Genetic Diseases and Dysmorphic syndromes
|
|
Roche |
ETROLIZUMAB |
Biodrugs/ Drugs |
Autoimmune & Inflammation
Musculoskeletal Disorders |
Irritable bowel syndrome |
3PhIII |
ETROLIZUMAB
Therapeutic area:
Autoimmune & Inflammation / Musculoskeletal Disorders
|
|
Roche |
DULIGOTUZUMAB |
Biodrugs/ Drugs |
Cancer |
Other malignant neoplasms of skin |
1PhI |
DULIGOTUZUMAB
Therapeutic area:
Cancer
|
|
Roche |
TASPOGLUTIDE |
Biodrugs/ Drugs |
Metabolic / Endocrinology |
Diabetes Mellitus |
3PhIII |
TASPOGLUTIDE
Therapeutic area:
Metabolic / Endocrinology
|
|
Roche |
IGF1R MAB |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasm without specification of site |
2PhII |
IGF1R MAB
Therapeutic area:
Cancer
|
|
Roche |
ONARTUZUMAB |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasm of bronchus and lung |
3PhIII |
ONARTUZUMAB
Therapeutic area:
Cancer
|
|
Roche |
XELODA |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasm of other and ill-defined sites |
2PhII |
XELODA
Therapeutic area:
Cancer
|
|
Roche |
ACTEMRA |
Biodrugs/ Drugs |
Metabolic / Endocrinology |
Thyrotoxicosis (hyperthyroidism) |
3PhIII |
ACTEMRA
Therapeutic area:
Metabolic / Endocrinology
|
|
Roche |
COBIMETINIB |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasms |
1PhI |
COBIMETINIB
Therapeutic area:
Cancer
|
|
Roche |
TASELISIB |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasm without specification of site |
1PhI |
TASELISIB
Therapeutic area:
Cancer
|
|
Roche |
ONARTUZUMAB |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasm of breast |
2PhII |
ONARTUZUMAB
Therapeutic area:
Cancer
|
|
Roche |
ERIVEDGE |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasm without specification of site |
2PhII |
ERIVEDGE
Therapeutic area:
Cancer
|
|
Roche |
DALCETRAPIB |
Biodrugs/ Drugs |
Cardiovascular and circulatory systems
Metabolic / Endocrinology |
Atherosclerosis |
3PhIII |
DALCETRAPIB
Therapeutic area:
Cardiovascular and circulatory systems / Metabolic / Endocrinology
|
|
Roche |
CMV ANTI |
Biodrugs/ Drugs |
Infections |
Cytomegaloviral disease |
2PhII |
CMV ANTI
Therapeutic area:
Infections
|
|
Roche |
GANTENERUMAB |
Biodrugs/ Drugs |
Central Nervous System |
Alzheimer's disease |
3PhIII |
GANTENERUMAB
Therapeutic area:
Central Nervous System
|
|
Roche |
EM RA PRED DEV |
Biodrugs/ Drugs |
Autoimmune & Inflammation
Digestive System |
Crohn's disease |
1PhI |
EM RA PRED DEV
Therapeutic area:
Autoimmune & Inflammation / Digestive System
|
|
Roche |
VALCYTE |
Biodrugs/ Drugs |
Autoimmune & Inflammation |
Transplanted organ and tissue status (Excl. complications) |
3PhIII |
VALCYTE
Therapeutic area:
Autoimmune & Inflammation
|
|
Roche |
IGF1R MAB |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasms |
2PhII |
IGF1R MAB
Therapeutic area:
Cancer
|
|
Roche |
ONARTUZUMAB |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasm of stomach |
3PhIII |
ONARTUZUMAB
Therapeutic area:
Cancer
|
|
Roche |
ZELBORAF |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasm without specification of site |
2PhII |
ZELBORAF
Therapeutic area:
Cancer
|
|
Roche |
AVASTIN |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasm of brain |
3PhIII |
AVASTIN
Therapeutic area:
Cancer
|
|
Roche |
VANUCIZUMAB |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasms |
1PhI |
VANUCIZUMAB
Therapeutic area:
Cancer
|
|
Roche |
PARSATUZUMAB |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasm of colon/rectum |
2PhII |
PARSATUZUMAB
Therapeutic area:
Cancer
|
|
Roche |
ERIVEDGE |
Biodrugs/ Drugs |
Autoimmune & Inflammation
Cancer |
Other disorders involving the immune mechanism |
2PhII |
ERIVEDGE
Therapeutic area:
Autoimmune & Inflammation / Cancer
|
|
Roche |
HCV POL INH PRO |
Biodrugs/ Drugs |
Infections |
Chronic viral haepatitis |
3PhIII |
HCV POL INH PRO
Therapeutic area:
Infections
|
|
Roche |
CRENEZUMAB |
Biodrugs/ Drugs |
Central Nervous System |
Alzheimer's disease |
3PhIII |
CRENEZUMAB
Therapeutic area:
Central Nervous System
|
|
Roche |
GAZYVA |
Biodrugs/ Drugs |
Blood and Lymphatic systems
Cancer |
Diffuse non-Hodgkin's lymphoma, unspecified |
3PhIII |
GAZYVA
Therapeutic area:
Blood and Lymphatic systems / Cancer
|
|
Roche |
ETROLIZUMAB |
Biodrugs/ Drugs |
Autoimmune & Inflammation
Digestive System |
Crohn's disease |
3PhIII |
ETROLIZUMAB
Therapeutic area:
Autoimmune & Inflammation / Digestive System
|
|
Roche |
XELODA |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasm of colon/rectum |
3PhIII |
XELODA
Therapeutic area:
Cancer
|
|
Roche |
IMGATUZUMAB |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasm of bronchus and lung |
2PhII |
IMGATUZUMAB
Therapeutic area:
Cancer
|
|
Roche |
PDL1 MAB |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasm of bladder |
3PhIII |
PDL1 MAB
Therapeutic area:
Cancer
|
|
Roche |
PDL1 MAB |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasm of kidney except renal pelvis |
2PhII |
PDL1 MAB
Therapeutic area:
Cancer
|
|
Roche |
AVASTIN |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasm of ovary |
3PhIII |
AVASTIN
Therapeutic area:
Cancer
|
|
Roche |
VENETOCLAX |
Biodrugs/ Drugs |
Blood and Lymphatic systems
Cancer |
Diffuse non-Hodgkin's lymphoma, unspecified |
1PhI |
VENETOCLAX
Therapeutic area:
Blood and Lymphatic systems / Cancer
|
|
Roche |
FORTOVASE |
Biodrugs/ Drugs |
Infections |
HIV disease unspecified |
2PhII |
FORTOVASE
Therapeutic area:
Infections
|
|
Roche |
LAMPALIZUMAB |
Biodrugs/ Drugs |
Ophthalmology and optometry |
Retinal disorders other |
4Reg. |
LAMPALIZUMAB
Therapeutic area:
Ophthalmology and optometry
|
|
Roche |
DANOPREVIR |
Biodrugs/ Drugs |
Infections |
Chronic viral haepatitis |
2PhII |
DANOPREVIR
Therapeutic area:
Infections
|
|
Roche |
GAZYVA |
Biodrugs/ Drugs |
Blood and Lymphatic systems
Cancer |
Follicular (nodular) non-Hodgkin's lymphoma |
3PhIII |
GAZYVA
Therapeutic area:
Blood and Lymphatic systems / Cancer
|
|
Roche |
IMGATUZUMAB |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasm of other and ill-defined sites |
1PhI |
IMGATUZUMAB
Therapeutic area:
Cancer
|
|
Roche |
ZELBORAF |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasms |
3PhIII |
ZELBORAF
Therapeutic area:
Cancer
|
|
Roche |
IMGATUZUMAB |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasm of colon/rectum |
2PhII |
IMGATUZUMAB
Therapeutic area:
Cancer
|
|
Roche |
PERJETA |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasm of breast |
3PhIII |
PERJETA
Therapeutic area:
Cancer
|
|
Roche |
CD40 IMAB |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasms |
1PhI |
CD40 IMAB
Therapeutic area:
Cancer
|
|
Roche |
PICTILISIB |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasm of breast |
2PhII |
PICTILISIB
Therapeutic area:
Cancer
|
|
Roche |
HERCEPTIN |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasm of bladder |
2PhII |
HERCEPTIN
Therapeutic area:
Cancer
|
|
Roche |
ALECTINIB |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasm of bronchus and lung |
3PhIII |
ALECTINIB
Therapeutic area:
Cancer
|
|
Roche |
MABTHERA |
Biodrugs/ Drugs |
Cardiovascular and circulatory systems |
Other necrotizing vasculopathies |
3PhIII |
MABTHERA
Therapeutic area:
Cardiovascular and circulatory systems
|
|
Roche |
DULIGOTUZUMAB |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasm of colon/rectum |
2PhII |
DULIGOTUZUMAB
Therapeutic area:
Cancer
|
|
Roche |
GAZYVA |
Biodrugs/ Drugs |
Blood and Lymphatic systems
Cancer |
Lymphoid leukaemia |
3PhIII |
GAZYVA
Therapeutic area:
Blood and Lymphatic systems / Cancer
|
|
Roche |
IMGATUZUMAB |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasms |
1PhI |
IMGATUZUMAB
Therapeutic area:
Cancer
|
|
Roche |
IPATASERTIB |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasm of breast |
2PhII |
IPATASERTIB
Therapeutic area:
Cancer
|
|
Roche |
PERJETA |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasm of ovary |
3PhIII |
PERJETA
Therapeutic area:
Cancer
|
|
Roche |
CEA CD3 TCB |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasms |
1PhI |
CEA CD3 TCB
Therapeutic area:
Cancer
|
|
Roche |
PICTILISIB |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasm of bronchus and lung |
2PhII |
PICTILISIB
Therapeutic area:
Cancer
|
|
Roche |
LIFASTUZUMAB VEDOTIN |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasm of ovary |
2PhII |
LIFASTUZUMAB VEDOTIN
Therapeutic area:
Cancer
|
|
Roche |
BITOPERTIN |
Biodrugs/ Drugs |
Central Nervous System |
Schizophrenia |
3PhIII |
BITOPERTIN
Therapeutic area:
Central Nervous System
|
|
Roche |
MABTHERA |
Biodrugs/ Drugs |
Autoimmune & Inflammation
Dermatology |
Pemphigus |
3PhIII |
MABTHERA
Therapeutic area:
Autoimmune & Inflammation / Dermatology
|
|
Roche |
DULIGOTUZUMAB |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasms |
2PhII |
DULIGOTUZUMAB
Therapeutic area:
Cancer
|
|
Roche |
GAZYVA |
Biodrugs/ Drugs |
Blood and Lymphatic systems
Cancer |
Malignant neoplasms of lymphoid haematopoietic + |
3PhIII |
GAZYVA
Therapeutic area:
Blood and Lymphatic systems / Cancer
|